The stock of Altimmune Inc (NASDAQ:ALT) last traded at $8.40, up 4.41% from the previous session.
ALT stock price is now 18.54% away from the 50-day moving average and 10.84% away from the 200-day moving average. The market capitalization of the company currently stands at $597.80M.
With the price target of $26, UBS recently initiated with Buy rating for Altimmune Inc (NASDAQ: ALT). , while ‘Goldman’ rates the stock as ‘Neutral’
In other news, Drutz David, Director sold 16,011 shares of the company’s stock on Aug 19 ’24. The stock was sold for $110,547 at an average price of $6.90. Upon completion of the transaction, the Director now directly owns 41,958 shares in the company, valued at $0.35 million. A total of 0.83% of the company’s stock is owned by insiders.
During the past 12 months, Altimmune Inc has had a low of $2.48 and a high of $14.84. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 16.87, and a quick ratio of 16.87. The fifty day moving average price for ALT is $7.0644 and a two-hundred day moving average price translates $7.593 for the stock.
The latest earnings results from Altimmune Inc (NASDAQ: ALT) was released for 2024-09-30. The net profit margin was -199076.92% and return on equity was -72.96% for ALT. The company reported revenue of $5000.0 for the quarter, compared to $0.36 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -98.62 percent. For the current quarter, analysts expect ALT to generate $620 in revenue.
